Skip to content

Occult Obscure Gastrointestinal Bleeding

Occult Obscure Gastrointestinal Bleeding (OGIB) in Colonic Diverticulitis Using Polyglucosamine: a Registry Study Following a Standard Management Protocol

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03464539
Acronym
OGIB
Enrollment
60
Registered
2018-03-14
Start date
2017-02-01
Completion date
2017-06-15
Last updated
2020-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Bleeding

Brief summary

To test the activity of a polyglucosamine (PG) together with a Standard Management protocol (SM) on the occult and obscure gastrointestinal bleeding (OGIB) and the clinical symptoms in patients suffering from colonic diverticulitis (CD).

Detailed description

The trial was conducted in a single center and subjects were participating to the San Valentino Vascular Screening Project (SVVSP). Sixty patients with history of colonic diverticulitis (CD) and occult obscure gastrointestinal bleeding (OGIB) were recruited. All subjects were following a Standard Management (SM) protocol consisting of diet and lifestyle modifications, and were freely choosing to be treated with polyglucosamine (PG) or to follow the SM only. Two groups of 30 cases each were formed and followed for 3 months. Diet was controlled three times (baseline and during the first and third month), through the Food Intake Assessment (FIA) which consisted of the weekly analysis of 25 different servings (e,g fruits, vegetables, pulses, first dish, meat, processed meat, cheese). The lifestyle modification consisted of physical exercise (9 MET (Metabolic Equivalents) -h/week of brisk walking) and oral hygiene. The main variable was OGIB, that was measured using Hemoccult Sensa Fecal Occult Blood Procedure. Ancillary variables where the hs-CRP (high sensitivity C Ractive Protein) and the daily gastrointestinal discomfort (GID) measured thorough a visual analogue scale (VAS) from 0 to 10. All variables were taken at baseline, after one and three months with the exception of GID that was measured also after one week of treatment.

Interventions

DIETARY_SUPPLEMENTPG low molecular weight chitosan

The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals

Sponsors

Blymum Srl
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Subjects aged between 55 to 65 years (males and females). * CD diagnosis. * DICA (Diverticular Inflammation and Complication Assessment) class DICA 2 or DICA 3. * OGIB positive to Hemoccult Sensa Fecal Occult Blood Procedure.

Exclusion criteria

* Subjects with Class DICA \> 3. * Therapy with mesalazine antibiotics and probiotics. * Cancer of any type (a part from benign polyposis), * Alcoholism. * Parkinsonism. * Alzheimer's Disease. * Severe depression. * Drug addiction.

Design outcomes

Primary

MeasureTime frameDescription
Change of Occult bleedingBaseline - 1 month - 3 monthsBleeding in feces

Secondary

MeasureTime frameDescription
Gastrointestinal discomfortBaseline - 1 week - 1 month - 3 monthsMeasurement through visual analogue scale

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026